Every investment decision must be based on an examination of an exhaustive set of information provided by the entrepreneur on his online profile. Spreds only proceeds to a limited verification of this information and does not control the investment opportunity within this company. Spreds did not verify the extent to which the business plan is deemed realistic and does not intervene with the final Information Note, including the retained maximum valuation. Spreds will align itself with the financial terms negotiated with the co-investor(s).
Fluigent is a Paris-based pioneering equipment manufacturer in microfluidics. Whether the application is with droplets, cell biology, particle studies, or in other research areas, Fluigent has the expertise and knowledge to provide the most cost effective and technically advanced solutions to the fluid control needs.
Microfluidics is the science of manipulating and controlling fluids in networks of channels with dimensions from tens to hundreds of micrometers.
- miniaturization: very small quantities, very high production rate, repeatability, fast reactions, lower costs => replacing an entire lab by a chip
- multiplexing: several analysis in parallel replacing several labs
- increasing precision
- cost & time savings
- smaller size (portability)
- higher reliability
In 2003 Jean-Louis Viovy and his team at the Curie Institute were facing issues with flow stabilization on a microfluidic experiment for DNA analysis. Stability and equilibration time of syringe pumps made the experiments long, tedious and not very reproducible. With J Lewiner, he has founded then, in 2006, the French company Fluigent as a spin off and introduced pressure-driven flow control pumps, as opposed to conventional syringe and peristaltic pumps. In 2008, Fluigent improved its product to monitor flow-rates. At that time, Fluigent was focusing on developing its pumps and providing specific tools for early cancerdetection. However, advances in genomic sequencing made the second activity outdated. In 2013, they decided to refocus the business and offer a modular solution for their flow sensors. The founders re-injected money, the CEO decided to leave the company and gave way to France Hamber, Fluigent’s current CEO. Since the company has been growing by 25% per year and Fluigent is now the world leader in fluid motion for the microfluidic market. The company exports in more than 40 countries, either directly, or via one of its thirteen distributors (for Asia, Middle East and Australia/New Zealand). The company has 2 Subsidiaries, one in Germany and one in the United States, and employs 40 people, including 7 PhD and 19 engineers. Fluigent’s ambition is to move from being the leader in microfluidics instrumentation to being the leader for providing global solutions for microfluidic applications to the research and industrial markets.
Fluigent is the partner to facilitate tomorrow's discoveries and accelerate their impact on society, in particular in the field of health and medicine, e.g. by reducing dose in therapy, replacing animal tests, etc.
Fluigent is committed to creating an impact for society on:
SDG#3 Good Health and Well-Being by supporting the research and development of vaccines and medicines, and SDG#8 Decent Work and Economic Growth by achieving full and productive employment and decent work for all women and men, including for young people and persons with disabilities and equal pay for work of equal value, and SDG#9 Industry, Innovation and infrastructure.
- Digital marketing;
- Communication (flyers, brochures, case studies, etc);
- Conferences: main channel because it gathers customers at the same place, avoids trips, and allows all team members to meet and understand clients’ needs
Fluigent has 2 different channels for commercialisation and exports in more than 40 countries:
1. Via its internal sales force: Fluigent has 2 wholly owned subsidiaries, one in Germany and another one in the United States;
2. Via distributors: 13 distributors in Asia (China, India, Korea, Japan, Taiwan, Singapore) Middle East, Australia and New Zealand. Its main distributor is in China. A distributorship agreement is concluded, generally with non exclusive competence.
Move from being the leader in microfluidic instrumentation to being the leader for providing global solutions for microfluidic applications, which are ease of use minimizing quantities of samples involved and automated.
- Exclusive license on two patents and & know how hold by Institut Marie Curie, with royalties’ equivalent to 2,5% of the net sales of the concerned Products. . This patent concerns « méthode de régulation de pression ». There is no possibility to buy back the patent but Fluigent will be able to transfer it.
Two patents have been filed by Fluigent:
1. Patent FRCM filed in 2012 which protects "la méthode de contrôle de débit par actionnement pneumatique dans un circuit microfluidique et l’implémentation de l’algorithme"("the method of control of flow by pneumatic actuation in a microfluid circuit and the implementation of the algorithm"). This patent has been granted in China, Japan, Korea and should be granted in the coming months in Europe, United States, Israel. This patent is completely independent from the patent Marie Curie.
2. Patent Flow EZ filed in 2017 which protects “le nouvel arrangement pneumatique ainsi que la stratégie de régulation ("the new pneumatic arrangement as well as the regulation strategy").
- Various trade-marks and model